磷酸化过氧化酶活化增生受体γ抗体 PPARγ

公司磷酸化过氧化酶活化增生受体γ抗体 PPARγ具有高纯度、高效价、高特异性的特点，仅用于科学研究，不可用于临床诊断及药物治疗，可以应用于多种实验。CST、Santa抗体品牌。

英文名称  Anti-Phospho-PPAR Gamma (ser273) 

中文名称  磷酸化过氧化酶活化增生受体γ抗体 PPARγ 

别    名  Phospho-PPAR Gamma(ser273); P-PPAR Gamma (Phospho-ser273); CIMT1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; PPAR gamma; PPARG; PPARG1; PPARG2; PPARG3; PPARG_HUMAN. 

浓    度  1mg/1ml 

规 格  0.1ml/100μg
磷酸化过氧化酶活化增生受体γ抗体 PPARγ的相关产品:

Rabbit Anti-Mink IgG  兔抗水貂IgG 1mg

Rabbit Anti-Mink IgG/Alexa Fluor 350  Alexa Fluor 350标记的兔抗水貂IgG 0.1ml 

磷酸化过氧化酶活化增生受体γ抗体 PPARγ抗体来源  Rabbit  

克隆类型  polyclonal 

交叉反应  Human, Mouse, Rat, Chicken, Pig, Cow, Rabbit, Sheep

产品类型  一抗  磷酸化抗体   

研究领域  肿瘤 细胞生物 信号转导 细胞凋亡 激酶和磷酸酶 表观遗传学  

蛋白分子量  predicted molecular weight: 57kDa 

性    状  Lyophilized or Liquid 

免 疫 原  KLH conjugated synthesised phosphopeptide derived from human PPAR Gamma around the phosphorylation site of ser273 

亚    型  IgG 

纯化方法  affinity purified by Protein A 

储 存 液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4 

产品应用   WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500 

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described.

Function : Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.

Subunit : Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with DNTTIP2, MAP2K1/MEK1, PRMT2 and TGFB1I1. Interacts with PDPK1. Interacts with ASXL1 AND ASXL2. 

Subcellular Location : Nucleus. Cytoplasm.

Tissue Specificity : Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

DISEASE : Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.

Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.

Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.

Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients 磷酸化过氧化酶活化增生受体γ抗体 PPARγwith sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Similarity : Belongs to the nuclear hormone receptor family. NR1 subfamily.

Contains 1 nuclear receptor DNA-binding domain. 

Database links : UniProtKB/Swiss-Prot: P37231.3

公司提供磷酸化过氧化酶活化增生受体γ抗体 PPARγ价格绝对优势，欢迎新老客户来电垂询我公司优质抗体磷酸化过氧化酶活化增生受体γ抗体 PPARγ说明书及报价等。